drugset / Trial / NCT03123952

Expanded Access to ABT-414

NCT03123952

Expanded access No longer available AbbVie

Summary

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to ABT-414 prior to approval by the local regulatory agency. Availability will depend on territory eligibility. Participating sites will be added as they apply for and are approved for the EAP. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Depatuxizumab mafodotin Other / unclassified Intravenous

Indications